- Trials with a EudraCT protocol (513)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
513 result(s) found for: Partial Thromboplastin Time.
Displaying page 1 of 26.
EudraCT Number: 2019-000285-38 | Sponsor Protocol Number: APHP190020 | Start Date*: 2019-08-21 |
Sponsor Name:London School of Hygiene and Tropical Medicine | ||
Full Title: Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers. | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016719-39 | Sponsor Protocol Number: 050901 | Start Date*: 2010-04-07 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: IMMUNINE – Purified Factor IX Concentrate Virus-Inactivated: A Phase IV, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors i... | |||||||||||||
Medical condition: To expose up to 50 patients aged 12-64 years, and approximately 20 pediatric patients up to 11 years of age with severe or moderately severe hemophilia B to IMMUNINE for a period of approximately 2... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004357-13 | Sponsor Protocol Number: CTH201401 | Start Date*: 2015-03-18 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Coagaulation in patients with atrial fibrillation: The effect of dabigatran | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003127-22 | Sponsor Protocol Number: SOG-CPE-2014-03 | Start Date*: 2015-01-13 | |||||||||||
Sponsor Name:SOGUG (Spanish Oncology Genitourinary Group) | |||||||||||||
Full Title: Phase II study with pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin based chemotherapy | |||||||||||||
Medical condition: Metastatic or locally advanced squamous penile carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005428-41 | Sponsor Protocol Number: 02044190615-01 | Start Date*: 2014-12-01 | ||||||||||||||||
Sponsor Name:Department of experimental and clincial medicine "F. Magrassi" | ||||||||||||||||||
Full Title: Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer | ||||||||||||||||||
Medical condition: The present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirim... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006958-31 | Sponsor Protocol Number: 2021/3401 | Start Date*: 2022-05-24 |
Sponsor Name:Gustave Roussy | ||
Full Title: An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | ||
Medical condition: Locally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005025-11 | Sponsor Protocol Number: BAY43-9006/13162 | Start Date*: 2009-05-06 | |||||||||||
Sponsor Name:Bayer Healthcare AG, D-51368 Leverkusen, Germany | |||||||||||||
Full Title: A Phase 2b, Double Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib Compared With Placebo When Administered in Combination With Chemotherapy (Modified FOLFOX6) for the Treatm... | |||||||||||||
Medical condition: The patient population includes patients with Stage IV metastatic colorectal cancer (mCRC), with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Patients must have measurable ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008532-82 | Sponsor Protocol Number: ARC1779-010b | Start Date*: 2009-02-19 |
Sponsor Name:Medical University of Vienna, Dept. of Clinical Pharmacology | ||
Full Title: A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779 Injection in Patients with von Willebrand Disease Type 2B | ||
Medical condition: von Willebrand Disease type 2B | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001443-31 | Sponsor Protocol Number: 1801 | Start Date*: 2018-11-21 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: DOAC Levels prior to Incision study: DALI study | ||
Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001576-11 | Sponsor Protocol Number: 4010-03-001 | Start Date*: 2019-09-10 | ||||||||||||||||
Sponsor Name:TESARO, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced... | ||||||||||||||||||
Medical condition: Recurrent or primary advanced (Stage III or IV) endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Ongoing) DK (Ongoing) NO (Ongoing) PL (Ongoing) FI (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) IT (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002374-46 | Sponsor Protocol Number: UC-0110/1807 | Start Date*: 2018-11-09 |
Sponsor Name:UNICANCER | ||
Full Title: A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas. | ||
Medical condition: Patients aged ≥18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016720-31 | Sponsor Protocol Number: 250901 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:Baxter Innovations GmbH [...] | |||||||||||||
Full Title: BAX 326 (recombinant Factor IX): A Phase 1/3 Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity in Previously Treated Patients with Severe (FIX... | |||||||||||||
Medical condition: Previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004686-13 | Sponsor Protocol Number: LAS-212 | Start Date*: 2020-05-01 |
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | ||
Full Title: An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement o... | ||
Medical condition: Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies due to liver disease and/or in pediatric patients requiring cardiac surgery or liver transplantation | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-005065-47 | Sponsor Protocol Number: TM-105 | Start Date*: 2018-05-15 |
Sponsor Name:TikoMed AB | ||
Full Title: A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis | ||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003300-12 | Sponsor Protocol Number: LOKON003 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:Lokon Pharma AB | |||||||||||||
Full Title: A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma | |||||||||||||
Medical condition: Malignant melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000826-31 | Sponsor Protocol Number: NN7999-3774 | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Novo Nordisk | |||||||||||||
Full Title: Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001486-67 | Sponsor Protocol Number: 101HEMB01 | Start Date*: 2016-07-21 | |||||||||||
Sponsor Name:Dimension Therapeutics, Inc. | |||||||||||||
Full Title: A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B | |||||||||||||
Medical condition: Moderate/severe to severe hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002437-19 | Sponsor Protocol Number: 251101 | Start Date*: 2011-10-28 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: BAX326 (RECOMBINANT FACTOR IX): A PHASE 2/3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY IN PREVIOUSLY TREATED PEDIATRIC PATIENTS W... | |||||||||||||
Medical condition: Pediatric previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002427-14 | Sponsor Protocol Number: 1199.9 | Start Date*: 2005-11-28 |
Sponsor Name:Boehringer Ingelheim Ltd | ||
Full Title: A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer | ||
Medical condition: Patients with relapsed ovarian carcinoma, fallopian tube carcinoma or primary peritoneal cancer of serous type who have responded to a 2nd, 3rd or 4th line chemotherapy regimen. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002566-40 | Sponsor Protocol Number: 20200491 | Start Date*: 2021-11-17 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatm... | |||||||||||||
Medical condition: Relapsed/Refractory Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DK (Ongoing) DE (Ongoing) GR (Ongoing) ES (Ongoing) PT (Completed) PL (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.